Twist Bioscience Sees Future Profitability on the Horizon
Twist Bioscience Corporation (NASDAQ: TWST) has recently reported its fourth-quarter financial performance, showcasing a mix of results that point to both challenges and opportunities. The company registered a loss of 45 cents per share, which was slightly wider than the forecasted loss of 43 cents. However, this loss comes against a backdrop of impressive sales growth.
In the fourth quarter, Twist Bioscience achieved sales of $99.01 million, reflecting a 17% increase compared to the previous year, and surpassing analyst expectations of $97.32 million. This growth is a positive indication of the company's underlying demand and market acceptance.
Moreover, the adjusted EBITDA loss narrowed to $7.8 million from $17 million in the same quarter last year. Such improvements in financial metrics suggest that the company's operational efficiency is improving as it continues to scale its production and services.
Innovative Product Shipments Fuel Growth
The company reported that it shipped products to approximately 3,800 customers during the year, up from about 3,550 the previous year. In addition, there was a significant increase in gene shipments, with Twist sending out around 938,000 genes, compared to 772,000 the year before. This surge in activity indicates a growing trust in Twist Bioscience's capabilities among its clients.
Furthermore, the gross margin for the fourth quarter experienced an uptick, rising to 51.3% from 45.1% a year earlier. This positive trend in gross margin underscores the company’s improvement in cost management and pricing strategy.
Future Prospects for Fiscal 2026
Looking forward, Twist Bioscience is optimistic about the upcoming fiscal year. The company projects sales in fiscal 2026 to be between $425 million and $435 million, which considerably exceeds the consensus prediction of $374.69 million. This ambitious target reflects confidence in the company's market position and product offering.
The revenue guidance includes anticipated earnings from DNA Synthesis and Protein Solutions of approximately $194 million to $199 million, alongside NGS Applications sales projected between $231 million and $236 million. Such diversity in revenue streams will be crucial for the company's overall growth.
Management expects the gross margin to remain above 52%, aligning with their strategic goals for efficiency and profitability.
First Quarter Expectations and Break-even Goals
For the first quarter of fiscal 2026, Twist expects to see sales between $100 million and $101 million, which aligns closely with analyst expectations of $100.34 million. Furthermore, the company aims to reach adjusted EBITDA breakeven by the fourth quarter of fiscal 2026, marking a significant milestone in its financial journey.
Dr. Emily M. Leproust, CEO and co-founder of Twist Bioscience, conveyed their commitment to entering a new growth phase with intentions to maintain gross margins above 50% and achieve sustainable profitability. Her leadership has been pivotal in steering the company towards these ambitious goals.
Analysts Review and Market Position
Analyst insights from William Blair indicate that shares of Twist Bioscience are trading at 3.9 times the expected 2026 sales, which is lower than the industry average of 6.3 times. Analyst Matt Larew expressed optimism regarding the long-term revenue potential, highlighting that the company’s strategic investments will enable it to tap into multiple lucrative markets.
In light of their efforts to moderate spending while scaling up, the company's narrative is one of rational growth and financial prudence, which could attract more investors in the long run. William Blair has rated the stock as Outperform, reflecting confidence in its future performance.
Current Market Position: As of the last market observation, TWST stock has seen a decline of 11.20%, trading at $26.55. This fluctuation is part of the dynamic nature of the biotech sector and user sentiment.
Frequently Asked Questions
What are the key financial outcomes for Twist Bioscience in the last quarter?
Twist Bioscience reported a loss of 45 cents per share with sales totaling $99.01 million, a 17% year-over-year increase.
What does the future look like for Twist Bioscience?
The company projects sales of $425 million to $435 million for fiscal 2026 and aims to achieve adjusted EBITDA breakeven by the fourth quarter.
How are analysts rating Twist Bioscience stocks?
Analysts from William Blair have assigned an Outperform rating, noting the stock trades below industry average multiples, suggesting potential for growth.
What are the company's sales expectations for the first quarter of 2026?
Twist expects sales between $100 million and $101 million for the first quarter, closely aligning with analyst estimates.
How has management acknowledged the company's growth and strategy?
Dr. Emily M. Leproust has emphasized maintaining strong gross margins and reaching profitability, signaling a clear path toward sustainable growth.
